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LETTERS TO THE EDITOR 
Effect of inhaled nitric oxide on left ventricular and 
pulmonary vascular function 
To the Editor: 
The conclusions of Argenziano and associates l contra-
dicted their evidence. They concluded: "Inhaled nitric oxide 
reduced pulmonary vascular resistance but did not alter 
myocardial contractility or diastolic function." However, 
their Table I showed the following evidence of increased 
left heart failure after their 6 experimental pigs inhaled 
nitric oxide (NO): Cardiac output and ejection fraction 
decreased while left ventricular end-diastolic volume and 
pressure increased. The authors cited 3 reports that left atri-
al pressure increased and pulmonary edema appeared when 
subjects with left ventricular dysfunction inhaled NO ther-
apeutically. This was further evidence that myocardial con-
tractility and diastolic function deteriorated after inhalation 
of NO. 
The authors' second point was that NO lowered the pul-
monary vascular resistance (PVR), which they calculated 
by the standard formula that is derived from Poiseuille's 
equation.2 However, "since the experiments from which the 
equation was derived were performed in straight, rigid tubes 
with steady, streamlined flow of an ideal, viscous fluid, the 
relationship cannot be directly applied to the vascular sys-
tem, in which the vessels are neither straight nor rigid, the 
blood is not a simple viscous fluid, and the flow is not 
always streamlined."2 
The common formula for "vascular resistance" is: 
PVR = PAP - LAP 
Cardiac output 
where PAP is mean pulmonary artery pressure and LAP is 
mean left atrial pressure. 
This can be misleading, because raising the left atrial 
pressure, which Argenziano and colleagues 1 observed in 
their pigs, decreases the numerator and thereby the calcu-
lated PVR. This can happen with no change in pulmonary 
artery pressure. Raising the left atrial pressure obviously 
obstructs pulmonary blood flow, but it decreases the calcu-
lated PVR. A similarly misleading result occurs when this 
formula is applied to systemic vascular resistance while 
phenyleprinei (Neo-Synephrine) is administered: The right 
atrial pressure increases more than the mean arterial pres-
sure increases, thereby decreasing the numerator in the re-
sistance equation. As a result, while vasoconstriction de-
creases the' force of the femoral pulses, the calculated 
systemic vascular resistance becomes abnormally low, the 
opposite of the true state. 
Although the number of pigs was too small to allow ade-
quate statistical evaluation of some measured parameters, the 
authors did show well that during controlled heart failure 
inhaled NO decreased pulmonary artery pressure despite ele-
vated left atrial pressure. 
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Reply to the Editor: 
We appreciate Dr Krohn's interest in our study and the 
opportunity to address his comments regarding our assess-
ment of myocardial function and the limitations associated 
with calculation of pulmonary vascular resistance. We 
respectfully disagree with Dr Krohn's assertion that our con-
clusions contradict our evidence. As mentioned in our article, 
previous reports of pulmonary edema and left atrial pressure 
elevation after administration of inhaled nitric oxide (iNa) in 
patients with myocardial dysfunction raised concerns about 
potential myocardial depressant effects of this agent. Our 
study was undertaken specifically to assess the effects of this 
pulmonary vasodilator on myocardial systolic and diastolic 
function. Because clinical hemodynamic parameters such as 
cardiac output and left ventricular end-diastolic pressure 
(LVEDP) are influenced by a number of factors (including 
preload, afterload, contractility, heart rate, and diastolic com-
pliance) in a complex fashion, these parameters cannot be 
individually used to accurately assess myocardial contractili-
ty or diastolic compliance unless all other factors (ie, preload, 
afterload, and heart rate) are accounted for. Therefore we 
assessed systolic function by 2 well-accepted load-indepen-
dent measures of contractility, the preload-recruitable stroke 
work relationship (PRSWR) and the end-systolic pressure-
volume relationship (ESPVR). We assessed diastolic function 
by the end-diastolic pressure-volume relation (EDPVR). Our 
data demonstrated clearly that despite slight increases in 
LVEDP, contractility and diastolic function as assessed by 
these measures was not altered by administration of iNa. Dr 
Krohn cites statistically insignificant decreases in cardiac out-
put and increases in left ventricular volume from Table I of 
our article as "evidence for deterioration of myocardial con-
tractility and diastolic dysfunction," but he ignores increases 
in mean arterial pressure and systemic vascular resistance and 
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